… ganciclovir alone. This study found that … CMV disease at 6 months from 44.3% for implant
plus placebo to 24.3% for implant plus oral ganciclovir and 19.6% for intravenous ganciclovir …

… and a concomitant CMV related myocarditis with favorable outcome after ganciclovir therapy.
… Treatment with IV ganciclovir was continued for 16 days and then patient was discharged …

… , 24), and additional intravenous or oral ganciclovir was needed. In this study, patients with
the presence of CMV-DNAemia or other active CMV diseases were all excluded to minimize …

… In conclusion, valganciclovir 450 mg enterally every 24 hours achieved goal ganciclovir
trough concentrations for CMV prophylaxis in most SOT patients receiving CVVHD. The …

… In a randomized clinical trial that compared 3 weeks of oral valganciclovir to intravenous
ganciclovir for treatment of CMV disease in 321 SOT recipients with mild-to-moderate …

… Standard of care for CMV-disease is still ganciclovir at 10 mg/kg bid Here we report data
about influence of non-CMV specific IVIG during ganciclovir treatment in allo-HSCT CMV+ …

… Only 10–15% of newborns infected with CMV infection have … therapies, such as intravenous
(IV) ganciclovir (GCV) and … the prevention and treatment of CMV infection in organ transplant …

… of CMV serology, blood and BAL CMV PCR, IV ganciclovir was started - 690 mg a day (5
mg/Kg IV q12 h) … In conclusion, severe CMV disease with lung involvement may occur, although …

… or intravenous (IV) ganciclovir (GCV) treatment in cases of isolated SNHL present in otherwise
asymptomatic CMV-… Here, we report the effects of GCV on SNHL in CMV-infected mice by …

… also be explained by hepatotoxic CMV disease, graft-versus-host disease of the liver or …
multiple ganciclovir concentrations to calculate AUC 24h . Moreover, ganciclovir concentrations …